Nicotine Dependence Market Forecast

Nicotine Dependence Market Forecast published by Datamonitor in April, 2009. This report price starts from US $ 15200.

Introduction

Abstract

With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence market represents a lucrative opportunity for pharmaceutical companies. With strong uptake since launch in 2006 of Pfizer' s Chantix (varenicline), the seven major prescription nicotine dependence market was estimated to total $1.35 billion in 2008.

• Benchmark key late-stage pipeline nicotine dependence projects against current market leading brands, supported by insight from key opinion leaders.
• Quantify the future market landscape with sales forecasts of marketed, generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.
• Understand key events impacting the future nicotine dependence prescription drug market

Table of Contents

OVERVIEW

• This product contains forecasts for prescribed nicotine dependence pharmacotherapies across the seven major markets from 2009 to 2018. It has been designed for delivery in an excel data pack format, but for more detail about this disease area please see the accompanying Pipeline and Commercial Insight: Nicotine Dependence word document and PowerPoint executive presentation (DMHC2482).
  • The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  • Introduction
  • Scope of this research
  • Research and analysis highlights
  • Key reasons to read this report

• Forecasting Methodology
  • The forecasting model:
  • General event information:
  • Event selection and quantification:
  • Event parameters:

Related Reports